Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 545Squamous Cell Carcinoma of Head and Neck 281Head and Neck Neoplasms 258Lung Neoplasms 240Uterine Cervical Neoplasms 182Stomach Neoplasms 172Esophageal Neoplasms 161Nasopharyngeal Carcinoma 127Urinary Bladder Neoplasms 117Esophageal Squamous Cell Carcinoma 116Neoplasms 115Small Cell Lung Carcinoma 106Ovarian Neoplasms 92Breast Neoplasms 92Neoplasm Metastasis 90Cholangiocarcinoma 77Carcinoma, Squamous Cell 76Pancreatic Neoplasms 73Biliary Tract Neoplasms 72Oropharyngeal Neoplasms 57Mesothelioma, Malignant 57Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 46Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Triple Negative Breast Neoplasms 39

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumors × Cisplatin × Clear all
NCT07268040 2026-01-12

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2 Recruiting
400 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡